BioWorld - Sunday, June 14, 2026

Articles Tagged with ''Genentech Inc.''

Pancreas puzzle with surgical tools

Uprising in pancreatic space more than Revolution

June 3, 2026
By Randy Osborne
No Comments
Oppenheimer analyst Jay Olson trumpeted “a new era” in pancreatic ductal adenocarcinoma (PDAC) after Revolution Medicines Inc.’s data splash with daraxonrasib at the American Society of Clinical Oncology meeting in Chicago – but he wasn’t talking about only that company. Combined with other recent updates in the space, the phase III data from Redwood City, Calif.-based Revolution is providing investors as well as patients with renewed hope in notoriously difficult-to-treat PDAC.
Read More
Cancer cell in the cross-hairs
Cancer

Selective CBL-B inhibitor with improved safety profile disclosed

April 9, 2026
No Comments
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune responses. In cancer, however, this inhibitory role can impair the immune system’s capacity to detect and eradicate tumor cells. Researchers from Genentech Inc. presented the design and optimization of a series of CBL-B-targeting molecular glues.
Read More
Clinical research concept with medical icons on light bulb
Biopharma clinical updates February 2026

Phase III wins lift shares of Compass, Palvella and Bridgebio in February

March 27, 2026
By Amanda Lanier
No Comments
BioWorld tracked 152 clinical trial readouts across phases I through III in February 2026, up from 144 in January but down from 215 in December. Of those, 20 phase III trials reported positive results, while one failed to meet key endpoints. By phase, February’s updates consisted of 50 from phase I, 46 from phase II and 57 from phase III.
Read More
Doctor giving medicine to patient

Pharma USA: R&D not enough – patients need better DTC access

March 16, 2026
By Karen Carey
No Comments
The disjointed health care system that patients face today blocks a significant proportion of them from accessing life-changing, innovative drugs, prompting many in the biopharma industry to explore more direct-to-consumer (DTC) pathways. During Pharma USA, a Reuters Events meeting held in Philadelphia March 16-17, executives from Eli Lilly and Co., Roche Holding AG’s Genentech unit, Amgen Inc. and consulting firm ZS Associates, among others, offered glimpses into a future where R&D is no longer enough.
Read More

Olema falls on Roche breast cancer failure with giredestrant

March 9, 2026
By Karen Carey
No Comments
The failure of the Persevera study, sponsored by Roche Holding AG’s Genentech unit, disrupts advancement of giredestrant in combination with palbociclib (Ibrance, Pfizer Inc.) as a first-line treatment for ER-positive, HER2-negative, locally advanced or metastatic breast cancer. For competitor Olema Pharmaceuticals Inc., which has palazestrant for the same indication, missing the phase III Persevera primary endpoint of progression-free survival translated to a 25.8% stock slide (NASDAQ:OLMA) to a $16 close on March 9.
Read More
Interfering RNA (RNAi)
Drug design, drug delivery & technologies

Genentech licenses Sanegene’s RNAi asset in $1.7B deal

Feb. 3, 2026
By Marian (YoonJee) Chu
No Comments
Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did not disclose specifics around the licensed candidate, except that it was derived from its LEAD (Ligand and Enhancer Assisted Delivery) platform.
Read More
T cells

Repertoire Decodes autoimmunity in $1.92B Eli Lilly deal

Jan. 29, 2026
By Karen Carey
No Comments
In its fourth major biopharma deal since its 2019 founding, Repertoire Immune Medicines signed a partnership with Eli Lilly and Co. to develop tolerizing therapies for several autoimmune diseases, gaining an up-front payment of $85 million, with a potential $1.84 billion in development and commercial milestone payments coming later, along with tiered royalties.
Read More